BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB; NFKB1; p105; p50) ImStar...
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...a test for rapid, early and accurate diagnosis of sepsis. June 2016 ImStar Therapeutics Inc. ImStar...
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...fumarate Preclinical FPRT Bio Inc. / Xencor Inc. (NASDAQ:XNCR) XPro1595 Dominant-negative inhibitor of TNFα Preclinical ImStar...
BioCentury | Feb 3, 2014
Emerging Company Profile

ImStar: Neuronal pacifier

...that leads to neurodegeneration has left drug developers hamstrung, with few good targets. Jean-Pierre Julien, ImStar's...
...active in many tissues. But for whatever reason, in ALS this processing goes awry," said ImStar...
...However, it does not have good drug-like properties and would not have been patentable. ImStar...
Items per page:
1 - 4 of 4
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB; NFKB1; p105; p50) ImStar...
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...a test for rapid, early and accurate diagnosis of sepsis. June 2016 ImStar Therapeutics Inc. ImStar...
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...fumarate Preclinical FPRT Bio Inc. / Xencor Inc. (NASDAQ:XNCR) XPro1595 Dominant-negative inhibitor of TNFα Preclinical ImStar...
BioCentury | Feb 3, 2014
Emerging Company Profile

ImStar: Neuronal pacifier

...that leads to neurodegeneration has left drug developers hamstrung, with few good targets. Jean-Pierre Julien, ImStar's...
...active in many tissues. But for whatever reason, in ALS this processing goes awry," said ImStar...
...However, it does not have good drug-like properties and would not have been patentable. ImStar...
Items per page:
1 - 4 of 4